<DOC>
	<DOC>NCT03015038</DOC>
	<brief_summary>Duration of each part of the study per patient: - Screening: From 1 to 4 weeks - Sampling period (blood and tissue): 1 day - Follow-up by patient: 60 months - Total study duration by patient: 84 months - Total inclusion duration: 24 months - Total Follow-up duration: 60 months - Total study duration: 84 months</brief_summary>
	<brief_title>Study of the Immune Response in Colon Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>1. Patients aged 18 or more. 2. Affiliation to a social security scheme 3. Diagnosis of a colon adenocarcinoma. 4. Patient have signed and dated consent of the study before undertaking procedures related to the study. 1. Patients under guardianship / curatorship 2. Following Situations Persons unable to understand, read and / or sign an informed consent Patient with the following functions: investigator or coinvestigator, research assistant, pharmacist, study coordinator or having any involvement in the study Uncooperative person or potentially noncompliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year. No affiliation to a social security scheme, a universal medical coverage or any similar plan. 3. Pregnant or lactating women. 4. Patients with HIV seropositivity. 5. Rectal tumor location.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>